| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Graft Occlusion, Vascular | D006083 | 11 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
| Neovascularization, Pathologic | D009389 | 39 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Dermatitis, Contact | D003877 | 59 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Pain | D010146 | 64 associated lipids |
| Autoimmune Diseases | D001327 | 27 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Genital Diseases, Female | D005831 | 7 associated lipids |
| Mouth Diseases | D009059 | 5 associated lipids |
| Meningococcal Infections | D008589 | 3 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Patel NP et al. | Treatment of eosinophilic pustulosis of infancy with topical tacrolimus. | 2012 | Br. J. Dermatol. | pmid:22563626 |
| Bens G et al. | Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. | 2003 | Br. J. Dermatol. | pmid:12890237 |
| Aoyama H et al. | Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. | 1995 | Br. J. Dermatol. | pmid:8547017 |
| Kyllönen H et al. | Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. | 2004 | Br. J. Dermatol. | pmid:15214906 |
| Murrell DF et al. | A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. | 2007 | Br. J. Dermatol. | pmid:17935515 |
| Liao YH et al. | Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. | 2007 | Br. J. Dermatol. | pmid:17935517 |
| Sugiura H et al. | An open study of a lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis. | 2001 | Br. J. Dermatol. | pmid:11736904 |
| Wu CS et al. | FK506 inhibits the enhancing effects of transforming growth factor (TGF)-β1 on collagen expression and TGF-β/Smad signalling in keloid fibroblasts: implication for new therapeutic approach. | 2012 | Br. J. Dermatol. | pmid:22540338 |
| Tennis P et al. | Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. | 2011 | Br. J. Dermatol. | pmid:21466537 |
| Afshar M et al. | The effect of pimecrolimus on innate immunity in subjects with atopic dermatitis: a double-blind, randomized, vehicle-controlled study. | 2013 | Br. J. Dermatol. | pmid:22577776 |
| Rigopoulos D et al. | Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. | 2004 | Br. J. Dermatol. | pmid:15541087 |
| RodrÃguez GarcÃa F et al. | Generalized pustular psoriasis successfully treated with topical tacrolimus. | 2005 | Br. J. Dermatol. | pmid:15787845 |
| Braza TJ et al. | Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. | 2003 | Br. J. Dermatol. | pmid:12828755 |
| Danby SG et al. | The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. | 2014 | Br. J. Dermatol. | pmid:24328907 |
| Chung BY et al. | The proactive treatment of atopic dermatitis with tacrolimus ointment in Korean patients: a comparative study between once-weekly and thrice-weekly applications. | 2013 | Br. J. Dermatol. | pmid:23110605 |
| Harth W and Linse R | Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. | 2004 | Br. J. Dermatol. | pmid:15099394 |
| Higgins E and Collins P | Recurrent bullous erythema multiforme treated with topical tacrolimus 0·1% ointment. | 2011 | Br. J. Dermatol. | pmid:21114481 |
| Pitt M et al. | A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. | 2006 | Br. J. Dermatol. | pmid:16704646 |
| Kanekura T et al. | Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. | 2003 | Br. J. Dermatol. | pmid:12588393 |
| Hashizume H et al. | Comparable risk of herpes simplex virus infection between topical treatments with tacrolimus and corticosteroids in adults with atopic dermatitis. | 2006 | Br. J. Dermatol. | pmid:16704659 |
| Katoh N et al. | Cutaneous sarcoidosis successfully treated with topical tacrolimus. | 2002 | Br. J. Dermatol. | pmid:12100200 |
| Hoeger PH et al. | The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. | 2009 | Br. J. Dermatol. | pmid:19067708 |
| Lan CC et al. | FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. | 2004 | Br. J. Dermatol. | pmid:15377358 |
| Vissers WH et al. | Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. | 2008 | Br. J. Dermatol. | pmid:18284400 |
| Piram M et al. | Short- and long-term outcome of linear morphoea in children. | 2013 | Br. J. Dermatol. | pmid:24032480 |
| Reitamo S et al. | 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. | 2004 | Br. J. Dermatol. | pmid:15030341 |
| Chuh AA | The application of topical tacrolimus in vesicular pemphigoid. | 2004 | Br. J. Dermatol. | pmid:15030368 |
| Gollnick H et al. | Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. | 2008 | Br. J. Dermatol. | pmid:18341665 |
| Erdogan M et al. | Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. | 2002 | Br. J. Dermatol. | pmid:12072063 |
| Hjelmgren J et al. | Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. | 2007 | Br. J. Dermatol. | pmid:17263826 |
| Nissi R et al. | Altered p53 and Bcl-2 expression in keratinocytes of vulvar lichen sclerosus during pimecrolimus treatment. | 2009 | Br. J. Dermatol. | pmid:19659469 |
| Spergel JM et al. | Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. | 2007 | Br. J. Dermatol. | pmid:17573885 |
| Taher ZA et al. | Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. | 2009 | Br. J. Dermatol. | pmid:19438859 |
| Undre NA et al. | Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. | 2009 | Br. J. Dermatol. | pmid:19076975 |
| Caproni M et al. | The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. | 2007 | Br. J. Dermatol. | pmid:17223872 |
| Bilenchi R et al. | Human papillomavirus reactivation following topical tacrolimus therapy of anogenital lichen sclerosus. | 2007 | Br. J. Dermatol. | pmid:17223903 |
| Niwa Y et al. | Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. | 2003 | Br. J. Dermatol. | pmid:14632799 |
| Mashiko M et al. | A case of angiolymphoid hyperplasia with eosinophilia successfully treated with tacrolimus ointment. | 2006 | Br. J. Dermatol. | pmid:16536847 |
| Ko MJ and Chu CY | Topical tacrolimus therapy for localized bullous pemphigoid. | 2003 | Br. J. Dermatol. | pmid:14632824 |
| Böhm M et al. | Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. | 2004 | Br. J. Dermatol. | pmid:15327576 |
| Hickey JR et al. | Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. | 2005 | Br. J. Dermatol. | pmid:15656817 |
| Mancuso G and Berdondini RM | Localized scleroderma: response to occlusive treatment with tacrolimus ointment. | 2005 | Br. J. Dermatol. | pmid:15656828 |
| Langeland T and Engh V | Topical use of tacrolimus and squamous cell carcinoma on the penis. | 2005 | Br. J. Dermatol. | pmid:15656830 |
| Kreuter A et al. | Pimecrolimus 1% cream for perianal atopic dermatitis. | 2005 | Br. J. Dermatol. | pmid:15656832 |
| Brouard MC et al. | Erosive pustular dermatosis of the leg: report of three cases. | 2002 | Br. J. Dermatol. | pmid:12366427 |
| Lewis FM and Neill SM | Safety of calcineurin inhibitors in the management of lichen sclerosis. | 2007 | Br. J. Dermatol. | pmid:17535239 |
| Queille-Roussel C et al. | The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. | 2001 | Br. J. Dermatol. | pmid:11260007 |
| Rao A and Bunker C | Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. | 2010 | Br. J. Dermatol. | pmid:20353455 |
| Oji V et al. | Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. | 2005 | Br. J. Dermatol. | pmid:16225628 |
| Connolly M and Kennedy C | Exfoliative cheilitis successfully treated with topical tacrolimus. | 2004 | Br. J. Dermatol. | pmid:15270904 |
| Tzung TY et al. | Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. | 2007 | Br. J. Dermatol. | pmid:17199600 |
| Poole CD et al. | Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study. | 2009 | Br. J. Dermatol. | pmid:19754867 |
| Chu CY | The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. | 2005 | Br. J. Dermatol. | pmid:15727676 |
| Park CW et al. | Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. | 2005 | Br. J. Dermatol. | pmid:15948978 |
| Gottlieb AB et al. | Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. | 2005 | Br. J. Dermatol. | pmid:15948985 |
| Bhol KC and Schechter PJ | Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. | 2005 | Br. J. Dermatol. | pmid:15948987 |
| Reitamo S et al. | A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. | 2005 | Br. J. Dermatol. | pmid:15948994 |
| Wolff K et al. | Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. | 2005 | Br. J. Dermatol. | pmid:15948996 |
| Rigopoulos D et al. | Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. | 2005 | Br. J. Dermatol. | pmid:15949015 |
| Kirtschig G et al. | Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. | 2002 | Br. J. Dermatol. | pmid:12207624 |
| Feldmann KA et al. | Is topical tacrolimus effective in alopecia areata universalis? | 2002 | Br. J. Dermatol. | pmid:12410729 |
| Weissenbacher S et al. | Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. | 2007 | Br. J. Dermatol. | pmid:17493072 |
| Williams HC | Preventing eczema flares with topical corticosteroids or tacrolimus: which is best? | 2011 | Br. J. Dermatol. | pmid:21271989 |
| Chohan R et al. | Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. | 2003 | Br. J. Haematol. | pmid:14510951 |
| Mehta RS et al. | Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. | 2016 | Br. J. Haematol. | pmid:26947769 |
| Pulsipher MA et al. | A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). | 2009 | Br. J. Haematol. | pmid:19744131 |
| Murata M et al. | A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. | 1999 | Br. J. Haematol. | pmid:10354150 |
| Armand P et al. | The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. | 2016 | Br. J. Haematol. | pmid:26729448 |
| Wong R et al. | Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. | 2003 | Br. J. Haematol. | pmid:12823354 |
| Feliu J et al. | Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies. | 2014 | Br. J. Haematol. | pmid:24962133 |
| Couriel DR et al. | Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. | 2005 | Br. J. Haematol. | pmid:16042691 |
| Mollee P et al. | Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. | 2001 | Br. J. Haematol. | pmid:11328304 |
| Kida A et al. | Calcineurin-inhibitor pain syndrome following haematopoietic stem cell transplantation. | 2004 | Br. J. Haematol. | pmid:15257699 |
| Boulad F et al. | Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. | 2000 | Br. J. Haematol. | pmid:11167755 |
| Dusting GJ et al. | Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. | 1999 | Br. J. Pharmacol. | pmid:10510443 |
| Quintá HR and Galigniana MD | The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. | 2012 | Br. J. Pharmacol. | pmid:22091865 |
| Gil V et al. | Effects of inhibitors of hydrogen sulphide synthesis on rat colonic motility. | 2011 | Br. J. Pharmacol. | pmid:21486289 |
| Magari K et al. | Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. | 2003 | Br. J. Pharmacol. | pmid:12839866 |
| Simon N et al. | Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria. | 2003 | Br. J. Pharmacol. | pmid:12540528 |
| Øzbay LA et al. | Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. | 2011 | Br. J. Pharmacol. | pmid:20825407 |
| Bader A et al. | Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. | 2000 | Br. J. Pharmacol. | pmid:10694240 |
| Squadrito F et al. | Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. | 1999 | Br. J. Pharmacol. | pmid:10385251 |
| Price RD et al. | FK506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway. | 2003 | Br. J. Pharmacol. | pmid:14559856 |
| Hortelano S et al. | Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. | 1999 | Br. J. Pharmacol. | pmid:10205001 |
| Harrison S et al. | Stimulation of airway sensory nerves by cyclosporin A and FK506 in guinea-pig isolated bronchus. | 1998 | Br. J. Pharmacol. | pmid:9884067 |
| Eum SY et al. | Inhibition by the immunosuppressive agent FK-506 of antigen-induced airways eosinophilia and bronchial hyperreactivity in mice. | 1997 | Br. J. Pharmacol. | pmid:9117088 |
| Yasutsune T et al. | Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery. | 1999 | Br. J. Pharmacol. | pmid:10188984 |
| Deters M et al. | Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. | 2002 | Br. J. Pharmacol. | pmid:12055139 |
| Waschulewski IH et al. | Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. | 1993 | Br. J. Pharmacol. | pmid:7683567 |
| Weidelt T and Isenberg G | Augmentation of SR Ca(2+) release by rapamycin and FK506 causes K(+)-channel activation and membrane hyperpolarization in bladder smooth muscle. | 2000 | Br. J. Pharmacol. | pmid:10742283 |
| Bas E et al. | Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. | 2012 | Br. J. Pharmacol. | pmid:22320124 |
| Gardiner SM et al. | Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. | 2004 | Br. J. Pharmacol. | pmid:14744807 |
| Pahl A et al. | Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy. | 2002 | Br. J. Pharmacol. | pmid:11959794 |
| Sakuma S et al. | FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. | 2000 | Br. J. Pharmacol. | pmid:10928971 |
| Seidel ER and Ragan VL | Inhibition by rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC-6 cells in culture. | 1997 | Br. J. Pharmacol. | pmid:9051292 |
| Harrison CA et al. | Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. | 2007 | Br. J. Pharmacol. | pmid:17200674 |
| Zuany-Amorim C et al. | Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. | 1993 | Br. J. Pharmacol. | pmid:7694762 |
| Li J et al. | Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II. | 2005 | Br. J. Pharmacol. | pmid:15821752 |
| Macfarlane SR et al. | The role of intracellular Ca2+ in the regulation of proteinase-activated receptor-2 mediated nuclear factor kappa B signalling in keratinocytes. | 2005 | Br. J. Pharmacol. | pmid:15821758 |
| Oetjen E et al. | The immunosuppressive drugs cyclosporin A and tacrolimus inhibit membrane depolarization-induced CREB transcriptional activity at the coactivator level. | 2005 | Br. J. Pharmacol. | pmid:15711594 |